Prime Peptides and Prime Sciences: Two Different FDA Letter Recipients
Updated August 23, 2026
Prime Peptides and Prime Sciences are different companies with different FDA warning letters. Prime Vitality Inc dba Prime Peptides received letter 695156-12102024 in the December 10, 2024 batch; Prime Sciences, of Scottsdale, Arizona, received letter 721805 in the March 31, 2026 batch. No relationship between the two appears in this index's record.
Side-by-side record
| Entity | Doing business as | Letter number | Batch date | Location |
|---|---|---|---|---|
| Prime Vitality Inc | Prime Peptides | 695156-12102024 | December 10, 2024 | Not captured by this index |
| Prime Sciences | Not captured by this index | 721805 | March 31, 2026 (posted April 7, 2026) | Scottsdale, AZ |
Two cells above print "Not captured by this index." No location for Prime Vitality Inc and no dba for Prime Sciences appear in the verified record this index keeps, so neither cell is filled in from secondary summaries. Both letters remain retrievable through the sources at the bottom of this page.
The December 2024 recipient
Prime Vitality Inc, doing business as Prime Peptides, is one of four research-peptide sellers that received FDA warning letters dated December 10, 2024. FDA identified the firm's semaglutide-, tirzepatide-, and retatrutide-class products as unapproved drugs, setting the research-use-only labeling against the firm's own published material. The December letters gave recipients 15 working days to respond in writing. The dedicated entry is the Prime Peptides letter record; the batch is tabulated at the December 10, 2024 batch record.
The March 2026 recipient
Prime Sciences, of Scottsdale, Arizona, is one of seven research-peptide sellers named in warning letters signed March 31, 2026 and posted to the FDA index on April 7, 2026. Two findings recur across that batch: therapeutic-effect descriptions on product pages, and administration supplies offered in the same cart as the compounds. The dedicated entry is the Prime Sciences letter record; the batch is tabulated at the April 2026 batch record.
Telling the records apart
Three fields separate the records cleanly. The letter numbers differ: 695156-12102024 against 721805. The batch dates sit more than fifteen months apart. And the documented findings differ: the December letter concerns GLP-1-class products identified as unapproved drugs on the strength of the firm's published material, while the March batch added the contents of the cart — administration supplies sold alongside the compounds — to the evidence the agency cited. A researcher matching press coverage to either company should match on the letter number and batch date, not on the word "Prime."
No corporate relationship between Prime Vitality Inc and Prime Sciences appears in the record this index keeps. The shared word in their trade names is the only overlap recorded here, beyond the fact that both received research-peptide warning letters. Each entity has its own entry in the vendor index.
Sources
- FDA Warning Letter, Prime Vitality Inc dba Prime Peptides, 695156-12102024. fda.gov
- FDA Warning Letters index (retrieves the Prime Sciences letter, 721805, by recipient name). fda.gov
- FDA Roundup, December 17, 2024. fda.gov
- Policy Canary analysis of the March 31, 2026 batch. policycanary.io
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.